Get your patient on Benzonatate - Benzonatate capsule (Benzonatate)

Medication interactionsSee all drug-to-drug interactions for this medication.
card icon

Benzonatate - Benzonatate capsule prescribing information

Indications & Usage

INDICATIONS & USAGE

Benzonatate USP is indicated for the symptomatic relief of cough.

Dosage & Administration

DOSAGE & ADMINISTRATION

Adults and Children over 10 years of age: Usual dose is one 100 mg, 150 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate should be swallowed whole . Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed.

Contraindications

CONTRAINDICATIONS

Hypersensitivity to benzonatate or related compounds.

Adverse Reactions

ADVERSE REACTIONS

Potential Adverse Reactions to benzonatate may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS : sedation; headache; dizziness; mental confusion; visual hallucinations.

GI : constipation; nausea; GI upset.

Dermatologic : pruritus; skin eruptions.

Other : nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.

Description

DESCRIPTION

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.


Referenced Image

Each soft gelatin capsule, for oral administration, contains 100 mg, 150 mg or 200 mg of benzonatate USP. Benzonatate Capsules, USP also contain the following inactive ingredients: D&C Yellow #10, gelatin, glycerin, purified water, methylparaben and propylparaben.


Pharmacology

CLINICAL PHARMACOLOGY

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

How Supplied/Storage & Handling

HOW SUPPLIED

Benzonatate Capsules USP, 100 mg: Yellow soft gelatin capsules, imprinted “105”, available in bottles of 100’s (NDC 67877-573-01), and 500’s (NDC 67877-573-05).


Benzonatate Capsules USP, 150 mg: Yellow soft gelatin capsules, imprinted "128", available in bottles of 100 (NDC 67877-574-01).


Benzonatate Capsules USP, 200 mg: Yellow soft gelatin capsules, imprinted “106”, available in bottles of 100’s (NDC 67877-575-01) and 500’s (NDC 67877-575-05).
Store at 20°C to 25° C (68°F to 77°F). [See USP Controlled Room Temperature]. PROTECT FROM LIGHT .

Manufactured by:
Softgel Healthcare Pvt. Ltd.,
Survey No. 20/1,
Vandalur-Kelambakkam Road,
Pudupakkam, Chengalpattu,
Tamilnadu - 603 103, India.

Distributed by:

Ascend Laboratories, LLC
Bedminster, NJ 07921


Revised: November 2025


PT3732-01 (2411326)

Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
Interactions Banner
Check medication interactionsReview interactions as part of your prescribing workflow

Benzonatate - Benzonatate capsule PubMed™ news

    Show the latest PubMed™ articles for Benzonatate - Benzonatate capsule